본문 바로가기
KERD
논문KCI 등재

Clinical Efficacy of Solifenacin in the Management of Diabetes Mellitus-Associated Versus Idiopathic Overactive Bladder Symptoms: A Multicenter Prospective Study

이동환|정성진|최훈|최종보|김준철|이광우|김영호|배재현|고우진|오철영|서주태
대한배뇨장애요실금학회 (Korean Continence Society)|2018.10|International Neurourology Journal|제22권 제1호|pp. 51-57

2

조회

0

다운로드

3

인용

0

참고문헌

키워드

Diabetes mellitusAnticholinergicsOveractive urinary bladder

초록

Purpose: To compare the clinical efficacy of anticholinergics for managing diabetes mellitus-associated overactive bladder (DM OAB) versus idiopathic overactive bladder (OAB) in Korean women. Methods: We conducted a multicenter, prospective, parallel-group, open-label, 12-week study. Women (20–65 years old) with OAB symptoms for over 3 months were assigned to the DM OAB and idiopathic OAB groups. Changes in the Overactive Bladder Symptom Score (OABSS), urgency, urinary urgency incontinence, nocturia, daytime frequency according to a voiding diary, uroflowmetry, and postvoid residual urine volume (PVR) at the first visit (V1), week 4 (V2), and week 12 (V3) were compared. Results: No significant difference was found between the baseline patient characteristics of the DM OAB and idiopathic OAB groups. Treatment with solifenacin was associated with improvements in urgency, urinary urgency incontinence, nocturia, frequency according to a voiding diary, and the total OABSS between V1 and V2 and between V1 and V3. Moreover, a significant improvement in urgency and urge incontinence was found between V2 and V3 in the DM OAB group. However, no significant changes were found in any other parameters. There were no significant differences between the DM OAB group and the idiopathic OAB group except for urgency and urge incontinence at V2 (3.71 vs. 2.28 and 0.47 vs. 0.32, respectively). Conclusions: The patients who received solifenacin demonstrated improved urgency, urinary urgency incontinence, nocturia, frequency according to a voiding diary, and total OABSS. Management with solifenacin was equally effective for both DM-related OAB and idiopathic OAB.

Abstract

Purpose: To compare the clinical efficacy of anticholinergics for managing diabetes mellitus-associated overactive bladder (DM OAB) versus idiopathic overactive bladder (OAB) in Korean women. Methods: We conducted a multicenter, prospective, parallel-group, open-label, 12-week study. Women (20–65 years old) with OAB symptoms for over 3 months were assigned to the DM OAB and idiopathic OAB groups. Changes in the Overactive Bladder Symptom Score (OABSS), urgency, urinary urgency incontinence, nocturia, daytime frequency according to a voiding diary, uroflowmetry, and postvoid residual urine volume (PVR) at the first visit (V1), week 4 (V2), and week 12 (V3) were compared. Results: No significant difference was found between the baseline patient characteristics of the DM OAB and idiopathic OAB groups. Treatment with solifenacin was associated with improvements in urgency, urinary urgency incontinence, nocturia, frequency according to a voiding diary, and the total OABSS between V1 and V2 and between V1 and V3. Moreover, a significant improvement in urgency and urge incontinence was found between V2 and V3 in the DM OAB group. However, no significant changes were found in any other parameters. There were no significant differences between the DM OAB group and the idiopathic OAB group except for urgency and urge incontinence at V2 (3.71 vs. 2.28 and 0.47 vs. 0.32, respectively). Conclusions: The patients who received solifenacin demonstrated improved urgency, urinary urgency incontinence, nocturia, frequency according to a voiding diary, and total OABSS. Management with solifenacin was equally effective for both DM-related OAB and idiopathic OAB.

참고문헌 (34)

  1. Yalla SV, "Correlation of American Urological Association symptom index with obstructive and nonobstructive prostatism", J Urol, 153(3 Pt 1), pp.674~679 (1995)[DOI]
  2. Jackson S, "The patient with an overactive bladder: symptoms and quality-of-life issues", Urology, 50(6A Suppl), pp.18~22 (1997)[DOI]
  3. Milsom I, "How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study", BJU Int, 87, pp.760~766 (2001)
  4. Brown JS, "Urinary incontinence in older women: who is at risk? Study of Osteoporotic Fractures Research Group", Obstet Gynecol, 87(5 Pt 1), pp.715~721 (1996)[DOI]
  5. Kim JC, "Changes of detrusor contractility and growth factors in streptozotocin-induced", Korean J Urol, 41, pp.615~621 (2000)
  6. Daneshgari F, "Diabetic bladder dysfunction: current translational knowledge", J Urol, 182(6 Suppl), pp.S18~S26 (2009)[DOI]
  7. Golbidi S, "Bladder dysfunction in diabetes mellitus", Front Pharmacol, 1, pp.136~ (2010)
  8. Wetle T, "Difficulty with holding urine among older persons in a geographically defined community: prevalence and correlates", J Am Geriatr Soc, 43, pp.349~355 (1995)[DOI]
  9. Brown JS, "Prevalence of urinary incontinence and associated risk factors in postmenopausal women. Heart & Estrogen", Progestin Replacement Study (HERS) Research Group, 1999, pp.94, 66~70
  10. Frimodt-Moller C, "Diabetic cystopathy: epidemiology and related disorders", Ann Intern Med, 92(2 Pt 2), pp.318~321 (1980)[DOI]
  11. Yoshimura N, "Recent advances in understanding the biology of diabetes-associated bladder complications and novel therapy", BJU Int, 95, pp.733~738 (2005)[DOI]
  12. Kaplan SA, "Urodynamic findings in patients with diabetic cystopathy", J Urol, 153, pp.342~344 (1995)[DOI]
  13. Brown JS, "Proceedings of the National Institute of Diabetes and Digestive and Kidney Diseases International Symposium on epidemiologic issues in urinary incontinence in women", Am J Obstet Gynecol, 188, pp.S77~S88 (2003)[DOI]
  14. Lee WC, "Investigation of urodynamic characteristics and bladder sensory function in the early stages of diabetic bladder dysfunction in women with type 2 diabetes", J Urol, 181, pp.198~203 (2009)
  15. Bansal R, "Urodynamic profile of diabetic patients with lower urinary tract symptoms: association of diabetic cystopathy with autonomic and peripheral neuropathy", Urology, 77, pp.699~705 (2011)[DOI]
  16. Liu RT, "Prevalence of overactive bladder and associated risk factors in 1359 patients with type 2 diabetes", Urology, 78, pp.1040~1045 (2011)[DOI]
  17. Cheung WW, "Prevalence of overactive bladder, its under-diagnosis, and risk factors in a male urologic veterans population", Int J Med Sci, 7, pp.391~394 (2010)
  18. Ohgaki K, "Association between metabolic syndrome and male overactive bladder in a Japanese population based on three different sets of criteria for metabolic syndrome and the Overactive Bladder Symptom Score", Urology, 79, pp.1372~1378 (2012)[DOI]
  19. Palleschi G, "Overactive bladder in diabetes mellitus patients: a questionnaire-based observational investigation", World J Urol, 32, pp.1021~1025 (2014)[DOI]
  20. Chiu AF, "Higher glycosylated hemoglobin levels increase the risk of overactive bladder syndrome in patients with type 2 diabetes mellitus", Int J Urol, 19, pp.995~1001 (2012)[DOI]
  21. Bang WJ, "Is type-2 diabetes mellitus associated with overactive bladder symptoms in men with lower urinary tract symptoms?", Urology, 84, pp.670~674 (2014)[DOI]
  22. Apfel SC, "Neurotrophic factors and diabetic peripheral neuropathy", Eur Neurol, 41(Suppl 1), pp.27~34 (1999)[DOI]
  23. Ozturk Y, "Effects of experimental diabetes and insulin on smooth muscle functions", Pharmacol Rev, 48, pp.69~112 (1996)
  24. Turner WH, "Smooth muscle of the bladder in the normal and the diseased state: pathophysiology, diagnosis and treatment", Pharmacol Ther, 75, pp.77~110 (1997)[DOI]
  25. Stevens LA, "Muscarinic receptor function, density and G-protein coupling in the overactive diabetic rat bladder", Auton Autacoid Pharmacol, 26, pp.303~309 (2006)[DOI]
  26. Yamaguchi C, "Overactive bladder in diabetes: a peripheral or central mechanism?", Neurourol Urodyn, 26, pp.807~813 (2007)[DOI]
  27. Chapple CR, "The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis", Eur Urol, 54, pp.543~562 (2008)[DOI]
  28. Schneider T, "Does concomitant diabetes affect treatment responses in overactive bladder patients?", Int J Clin Pract, 67, pp.1138~1143 (2013)[DOI]
  29. Yono M, "Effect of insulin treatment on tissue size of the genitourinary tract in BB rats with spontaneously developed and streptozotocin-induced diabetes", Naunyn Schmiedebergs Arch Pharmacol, 372, pp.251~255 (2005)[DOI]
  30. Christ GJ, "Effects of streptozotocin-induced diabetes on bladder and erectile (dys)function in the same rat in vivo", BJU Int, 97, pp.1076~1082 (2006)[DOI]
  31. Tong YC, "Changes in bladder nerve-growth factor and p75 genetic expression in streptozotocin-induced diabetic rats", BJU Int, 96, pp.1392~1396 (2005)[DOI]
  32. Wu MY, "Risks of nocturia in patients with chronic kidney disease--do the metabolic syndrome and its components matter?", J Urol, 188, pp.2269~2273 (2012)[DOI]
  33. Kupelian V, "Association of C-reactive protein and lower urinary tract symptoms in men and women: results from Boston Area Community Health survey", Urology, 73, pp.950~957 (2009)[DOI]
  34. Chung MS, "Prevalence and associated risk factors of nocturia and subsequent mortality in 1,301 patients with type 2 diabetes", Int Urol Nephrol, 46, pp.1269~1275 (2014)[DOI]

이 간행물의 다른 논문 (29건)

Importance of Central Regulation for Lower Urinary Tract Functions조영삼pp. 1-1Animal Model of Interstitial Cystitis/Bladder Pain Syndrome권휘안pp. 1-2Central Regulation of Micturition and Its Association With Epilepsy권민정, 장현종, 조경옥pp. 2-8Animal Modelling of Interstitial Cystitis/Bladder Pain SyndromeKarl-Erik Andersson, Lori Birderpp. 3-9Synergistic Activities of Abdominal Muscles Are Required for Efficient Micturition in Anesthetized Female MiceAlvaro Munoz, Yolanda Cruz, Yingchun Zhang, Chuan Zhang, Timothy B. Boonepp. 9-19
원문 보기